Toll Free: 1-888-928-9744

Chondrosarcoma - Pipeline Review, H2 2016

Published: Nov, 2016 | Pages: 148 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Chondrosarcoma - Pipeline Review, H2 2016

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Chondrosarcoma - Pipeline Review, H2 2016, provides an overview of the Chondrosarcoma (Oncology) pipeline landscape.

Chondrosarcoma is a malignant cancer whose tumor cells produce a pure hyaline cartilage that results in abnormal bone and/or cartilage growth. Signs and symptoms include pain in the affected area that may worsen at night or during physical activity, swelling in the painful area, a lump or mass, enlargement of an existing growth, limping, difficulty moving the affected limb, changes in urination. Treatment includes chemotherapy and radiation therapy. 

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Chondrosarcoma - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Chondrosarcoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Chondrosarcoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Chondrosarcoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II and Phase I stages are 7 and 3 respectively. Similarly, the Universities portfolio in Phase II and Discovery stages comprises 1 and 1 molecules, respectively.Chondrosarcoma.

Chondrosarcoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Chondrosarcoma (Oncology).
- The pipeline guide reviews pipeline therapeutics for Chondrosarcoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources. 
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Chondrosarcoma (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Chondrosarcoma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects. 
- The pipeline guide reviews latest news related to pipeline therapeutics for Chondrosarcoma (Oncology)

Reasons To Buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Chondrosarcoma (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Chondrosarcoma (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
 Table of Contents
Table of Contents 2 List of Tables 4 List of Figures 5 Introduction 6 Global Markets Direct Report Coverage 6 Chondrosarcoma Overview 7 Therapeutics Development 8 Pipeline Products for Chondrosarcoma - Overview 8 Pipeline Products for Chondrosarcoma - Comparative Analysis 9 Chondrosarcoma - Therapeutics under Development by Companies 10 Chondrosarcoma - Therapeutics under Investigation by Universities/Institutes 11 Chondrosarcoma - Pipeline Products Glance 12 Clinical Stage Products 12 Early Stage Products 13 Chondrosarcoma - Products under Development by Companies 14 Chondrosarcoma - Products under Investigation by Universities/Institutes 15 Chondrosarcoma - Companies Involved in Therapeutics Development 16 Agios Pharmaceuticals, Inc. 16 Celgene Corporation 17 CytRx Corporation 18 EpiZyme, Inc. 19 Horizon Pharma Plc 20 Karyopharm Therapeutics, Inc. 21 Merck & Co., Inc. 22 Novartis AG 23 Pfizer Inc. 24 Chondrosarcoma - Therapeutics Assessment 25 Assessment by Monotherapy Products 25 Assessment by Target 26 Assessment by Mechanism of Action 28 Assessment by Route of Administration 30 Assessment by Molecule Type 32 Drug Profiles 34 AG-120 - Drug Profile 34 Product Description 34 Mechanism Of Action 34 R&D Progress 34 aldoxorubicin hydrochloride - Drug Profile 38 Product Description 38 Mechanism Of Action 38 R&D Progress 38 axitinib - Drug Profile 54 Product Description 54 Mechanism Of Action 54 R&D Progress 54 enasidenib mesylate - Drug Profile 60 Product Description 60 Mechanism Of Action 60 R&D Progress 60 interferon gamma-1b - Drug Profile 66 Product Description 66 Mechanism Of Action 66 R&D Progress 66 pazopanib hydrochloride - Drug Profile 70 Product Description 70 Mechanism Of Action 70 R&D Progress 70 pembrolizumab - Drug Profile 77 Product Description 77 Mechanism Of Action 77 R&D Progress 77 Peptide to Inhibit c-Myc and mTOR for Chondrosarcoma and Oncology - Drug Profile 114 Product Description 114 Mechanism Of Action 114 R&D Progress 114 Peptide to Target COX-2 and MAS-GPCR for Oncology - Drug Profile 115 Product Description 115 Mechanism Of Action 115 R&D Progress 115 selinexor - Drug Profile 117 Product Description 117 Mechanism Of Action 117 R&D Progress 117 sirolimus - Drug Profile 136 Product Description 136 Mechanism Of Action 136 R&D Progress 136 tazemetostat - Drug Profile 137 Product Description 137 Mechanism Of Action 137 R&D Progress 137 Chondrosarcoma - Dormant Projects 145 Chondrosarcoma - Discontinued Products 146 Appendix 147 Methodology 147 Coverage 147 Secondary Research 147 Primary Research 147 Expert Panel Validation 147 Contact Us 147 Disclaimer 148
List of Tables
Number of Products under Development for Chondrosarcoma, H2 2016 8 Number of Products under Development for Chondrosarcoma - Comparative Analysis, H2 2016 9 Number of Products under Development by Companies, H2 2016 10 Number of Products under Investigation by Universities/Institutes, H2 2016 11 Comparative Analysis by Clinical Stage Development, H2 2016 12 Comparative Analysis by Early Stage Development, H2 2016 13 Products under Development by Companies, H2 2016 14 Products under Investigation by Universities/Institutes, H2 2016 15 Chondrosarcoma - Pipeline by Agios Pharmaceuticals, Inc., H2 2016 16 Chondrosarcoma - Pipeline by Celgene Corporation, H2 2016 17 Chondrosarcoma - Pipeline by CytRx Corporation, H2 2016 18 Chondrosarcoma - Pipeline by EpiZyme, Inc., H2 2016 19 Chondrosarcoma - Pipeline by Horizon Pharma Plc, H2 2016 20 Chondrosarcoma - Pipeline by Karyopharm Therapeutics, Inc., H2 2016 21 Chondrosarcoma - Pipeline by Merck & Co., Inc., H2 2016 22 Chondrosarcoma - Pipeline by Novartis AG, H2 2016 23 Chondrosarcoma - Pipeline by Pfizer Inc., H2 2016 24 Assessment by Monotherapy Products, H2 2016 25 Number of Products by Stage and Target, H2 2016 27 Number of Products by Stage and Mechanism of Action, H2 2016 29 Number of Products by Stage and Route of Administration, H2 2016 31 Number of Products by Stage and Molecule Type, H2 2016 33 Chondrosarcoma - Dormant Projects, H2 2016 145 Chondrosarcoma - Discontinued Products, H2 2016 146



                                

To request a free sample copy of this report, please complete the form below.

We never share your personal data. Privacy policy
Interested in this report? Get your FREE sample now! Get a Free Sample
Choose License Type
Single User - US $2000
Multi User - US $4000
Hexareeasearch Know

Did you know?

Research Assistance

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Why to buy from us

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Information security

Your personal and confidential information is safe and secure.

verify